Published in Clin Exp Metastasis on January 01, 2004
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res (2008) 1.07
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 0.93
Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. PLoS One (2011) 0.88
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J Oncol (2009) 0.87
Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol (2012) 0.84
Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol (2010) 0.82
The biology and clinical implications of prostate cancer dormancy and metastasis. J Mol Med (Berl) (2015) 0.81
Promoter analysis of human glutamate carboxypeptidase II. Brain Res (2007) 0.80
Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.78
Minimal residual disease in melanoma: circulating melanoma cells and predictive role of MCAM/MUC18/MelCAM/CD146. Cell Death Discov (2017) 0.75
Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer. Indian J Nucl Med (2017) 0.75
Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet (1995) 5.77
Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res (1990) 5.41
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res (1974) 3.96
Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics (1982) 2.74
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med (2001) 2.49
Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology (1994) 2.41
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol (1997) 2.28
Screening for prostatic carcinoma with prostate specific antigen. J Urol (1992) 2.03
Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology (1995) 2.00
Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem (1998) 1.99
Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer (1995) 1.93
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol (2000) 1.89
The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol (1998) 1.86
Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol (1997) 1.55
Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res (1997) 1.23
Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol (1997) 1.13
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol (1997) 1.12
Sensitivity or specificity of reverse transcriptase-polymerase chain reaction assays: the real challenge for molecular staging of prostatic carcinomas. Int J Cancer (1998) 1.08
Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol (2000) 1.03
Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology (1997) 0.98
Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med (1993) 0.96
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol (2003) 0.95
Identification of bone marrow micrometastases in patients with prostate cancer. Cancer (1994) 0.95
Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer (1997) 0.92
Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology (1999) 0.92
Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res (1998) 0.90
Molecular staging of prostate cancer: dream or reality? Oncology (Williston Park) (1999) 0.86
Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate (2001) 0.86
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience. Mol Urol (2000) 0.84
The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol (1997) 0.84
Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff. Eur Urol (2001) 0.82
Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer (1997) 0.82
A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab (2001) 0.81
The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol (1996) 0.81
Reverse transcriptase-polymerase chain reaction assays for prostate cancer. Urol Clin North Am (1997) 0.80
Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metastasis (1999) 0.79
Detection of illegitimate transcripts of prostate-specific antigen mRNA in blood by reverse transcription-polymerase chain reaction. Int J Cancer (1998) 0.79
Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology (1997) 0.77
The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am (1996) 0.77
Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Urol Clin North Am (1997) 0.77
Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol (1996) 0.75
Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res (2002) 0.75
The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am (2001) 0.75
Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol (1997) 0.75
The role of adiponectin in human vascular physiology. Int J Cardiol (2011) 2.24
Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension (2011) 1.67
The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets (2004) 1.48
Colorectal cancer stem cells. Stem Cells (2012) 1.47
Circadian rhythm disruption in cancer biology. Mol Med (2012) 1.31
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab (2010) 1.24
Muscle regeneration: cellular and molecular events. In Vivo (2009) 1.23
Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther (2009) 1.22
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo (2007) 1.10
IGF-1 expression in infarcted myocardium and MGF E peptide actions in rat cardiomyocytes in vitro. Mol Med (2009) 1.08
Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity. Anticancer Res (2004) 1.04
Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.04
The kisspeptin (KiSS-1)/GPR54 system in cancer biology. Cancer Treat Rev (2008) 1.03
Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res (2007) 1.01
Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists. Expert Opin Investig Drugs (2003) 1.00
The glutamatergic system expression in human PC-3 and LNCaP prostate cancer cells. Anticancer Res (2009) 0.99
Cytokines in muscle damage. Adv Clin Chem (2012) 0.98
Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care (2013) 0.96
Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer (2011) 0.96
Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J Steroid Biochem Mol Biol (2008) 0.94
Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol Med (2008) 0.93
Circulating tumor cells in colorectal cancer: detection methods and clinical significance. Anticancer Res (2009) 0.92
The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines. Expert Opin Ther Targets (2007) 0.91
Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res (2005) 0.91
The glutamatergic system outside the CNS and in cancer biology. Expert Opin Investig Drugs (2005) 0.91
Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res (2005) 0.89
Male breast adenocarcinoma in a prostate cancer patient following prolonged anti-androgen monotherapy. Anticancer Res (2004) 0.89
p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer. In Vivo (2005) 0.89
Kiss-1/GPR54 protein expression in breast cancer. Anticancer Res (2014) 0.88
Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies. Int J Inflam (2012) 0.88
Human vascular endothelial cells with extended life spans: in vitro cell response, protein expression, and angiogenesis. Angiogenesis (2002) 0.88
Syndrome of inappropriate antidiuretic hormone secretion in a patient with hormone refractory prostate cancer. Anticancer Res (2003) 0.88
Detection of circulating tumor cells in bladder cancer patients. Cancer Treat Rev (2008) 0.86
IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells. Anticancer Res (2009) 0.86
Insulin-like growth factor-1 isoform mRNA expression in women with endometriosis: eutopic endometrium versus endometriotic cyst. Ann N Y Acad Sci (2006) 0.85
Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate (2004) 0.85
Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med (2009) 0.85
Detection of the circulating tumor cells in cancer patients. Future Oncol (2010) 0.85
Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement. Anticancer Res (2003) 0.84
Glutamatergic system in bone physiology. In Vivo (2004) 0.84
Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res (2004) 0.84
Preoperative serum lactate dehydrogenase levels in colorectal and gastric cancer: a hospital-based case-control study. Biomark Med (2013) 0.83
Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res (2006) 0.83
Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res (2006) 0.83
Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol (2010) 0.82
Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev (2010) 0.82
Systemic cytokine response following exercise-induced muscle damage in humans. Clin Chem Lab Med (2009) 0.82
KISS1 expression in colorectal cancer. APMIS (2013) 0.81
Autophagy: a target for therapeutic interventions in myocardial pathophysiology. Expert Opin Ther Targets (2008) 0.81
Serum testosterone: A potentially adjunct screening test for the assessment of the risk of prostate cancer among men with modestly elevated PSA values (> or =3.0 and <10.0 ng/ml). Anticancer Res (2006) 0.81
Insulinlike growth factor-1Ec (MGF) expression in eutopic and ectopic endometrium: characterization of the MGF E-peptide actions in vitro. Mol Med (2010) 0.80
Calcium and vitamin D supplementation through fortified dairy products counterbalances seasonal variations of bone metabolism indices: the Postmenopausal Health Study. Eur J Nutr (2010) 0.80
Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer. Front Endocrinol (Lausanne) (2013) 0.80
Dietary glycotoxins affect scavenger receptor expression and the hormonal profile of female rats. J Endocrinol (2013) 0.80
IGF1Ec expression in MG-63 human osteoblast-like osteosarcoma cells. Anticancer Res (2011) 0.79
MG-63 osteoblast-like cells enhance the osteoprotegerin expression of PC-3 prostate cancer cells. Anticancer Res (2009) 0.79
Spirometric reference values in greek children and adolescents. In Vivo (2010) 0.79
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. Urology (2004) 0.79
Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers. Clin Lung Cancer (2013) 0.79
Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs (2013) 0.79
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach. Expert Opin Investig Drugs (2006) 0.79